GO
Loading...

Genentech Warns of Stroke Risk for Blindness Drug Users

Genentech has sent a letter alerting eye doctors to the risk of stroke from Lucentis, its drug for treating age-related macular degeneration, a spokeswoman said.

The letter was a "proactive effort" to advise doctors that an interim analysis of a large 5,000-patient trial shows that 1.2% of patients given a 0.5-milligram dose of the drug suffered a stroke, compared with 0.3% of patients given a 0.3-mg dose, said spokeswoman Dawn Kalmar.

She said the findings mirror those shown in previous trials of Lucentis, which was approved by the U.S. Food and Drug Administration last year.

Featured

  • The Marriner S. Eccles Federal Reserve building in Washington.

    CNBC's Fed Survey shows market pros aren't very confident the Fed can end its easy money polices without a market crash, a recession or bad inflation.

  • Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported better-than-expected results, with sales of newer drugs offsetting declining sales of drugs facing generic competition.

  • Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • An attendee is silhouetted against a Microsoft poster at the Microsoft Developers Build Conference in San Francisco, April 2, 2014.

    An agency that enforces antimonopoly laws visited company offices in four cities, as the country more closely scrutinizes multinational companies.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video